OncoMatch/Clinical Trials/NCT05494060
XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma
Is NCT05494060 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Anlotinib hydrochloride capsule and Penpulimab for carcinoma.
Treatment: Anlotinib hydrochloride capsule · Penpulimab · XELOX — This is an open label, randomized, phase Ⅱ, multi-cohort study to treat subjects with ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma. The patients will be randomized into two arms consist of Penpulimab + Anlotinib (3 weeks/cycle) + XELOX and XELOX at a ratio of 1:1. This study is conducted to assess safety and anti-tumor activity of the monoclonal antibody Penpulimab in combination with Anlotinib and standard chemotherapy as adjuvant treatment for ctDNA-positive Gastric, or Gastroesophageal Junction Carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Disease stage
Required: Stage III
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: surgery — radical resection (D2, R0 or R1)
had been treated with Radical resection (D2, R0 or R1) of gastric cancer
Cannot have received: immune targeted therapy
Previous use of immune targeted therapy drugs
Lab requirements
Blood counts
Hemoglobin ≥90 g/L; Neutrophil count ≥1.5×10^9/L; Platelet count ≥100×10^9/L
Kidney function
Serum creatinine ≤1.5 ULN or creatinine clearance ≥60mL/min
Liver function
Total bilirubin≤1.5×ULN; ALT and AST ≤ 2.5×ULN; if liver metastasis, ALT and AST ≤ 5×ULN
Cardiac function
No obvious clinical symptoms of heart disease
The main organs are functioning well, and the blood test results within 14 days before enrollment should meet the following requirements: ... No obvious clinical symptoms of heart disease.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify